124 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
and are subject to known and unknown risks, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts … and Drug Administration (FDA). No representation is made as to the safety or effectiveness of these product candidates for the use for which such product
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
◦One cohort … of treatment data expected in the fourth quarter of 2024. The trial is evaluating the safety, tolerability and antiviral activity of the combination
8-K
EX-99.1
VIR
Vir Biotechnology Inc
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
trials, including the enrollment of
Vir’s clinical trials, and the expected timing of data readouts and presentations; the potential benefits, safety
8-K
EX-99.1
293jo9hlf z5
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
swu84bah9 nle
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
S-3ASR
EX-1.2
1aapx tpaxve7v8
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
thy0czd7y pzj
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
4qq 5h1675w4tzt6vb59
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
5iwgzmet6wsi 5w4p9
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
xq0 juna4rol5s8e1bu
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
kdrjyqk89lq fa4vvpxo
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
q3f4p
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm